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N E U R O S C I E N C E
Behavioral and epigenetic consequences of oxytocin 
treatment at birth
W. M. Kenkel1,2*, A.-M. Perkeybile1, J. R. Yee1,3, H. Pournajafi-Nazarloo1, T. S. Lillard4, 
E. F. Ferguson4, K. L. Wroblewski4, C. F. Ferris3, C. S. Carter1†, J. J. Connelly4†
Oxytocin is used in approximately half of all births in the United States during labor induction and/or augmentation. 
However, the effects of maternal oxytocin administration on offspring development have not been fully charac-
terized. Here, we used the socially monogamous prairie vole to examine the hypothesis that oxytocin exposure at 
birth can have long-term developmental consequences. Maternally administered oxytocin increased methylation 
of the oxytocin receptor (Oxtr) in the fetal brain. As adults, oxytocin-exposed voles were more gregarious, with 
increased alloparental caregiving toward pups and increased close social contact with other adults. Cross-fostering 
indicated that these effects were the result of direct action on the offspring, rather than indirect effects via post-
natal changes in maternal behavior. Male oxytocin-exposed offspring had increased oxytocin receptor density and 
expression in the brain as adults. These results show that long-term effects of perinatal oxytocin may be mediated 
by an epigenetic mechanism.
INTRODUCTION
The hormone oxytocin (OXT) triggers uterine contractions at birth, 
facilitating expulsion of the fetus. In contemporary obstetric care, OXT 
is the most widely used uterotonic agent (1) and is used to both in-
duce and augment labor. Since 1990, the rate of labor induction in 
the United States has increased from 9.5 to 23.8% of births in 2015 
(2). When including labor augmentation, national surveys estimate 
that approximately 50% of women receive some form of exogenous 
OXT during labor (3, 4). Conversely, infants delivered by cesarean 
section have lower levels of OXT than those delivered vaginally (5). 
It has conventionally been thought that maternal OXT would nei-
ther reach the fetus nor produce long-lasting effects. However, this 
assumption has not been thoroughly tested.
What might be the consequences on offspring neurodevelopment 
as a result of exogenous OXT administration at birth? OXT serves a 
variety of functions in the neonate, all broadly related to helping achieve 
a transition from the uterine environment to the gradual process of 
establishing homeostatic independence (6). These functions in the 
fetus/neonate are analogous to how OXT triggers the onset of ma-
ternal behavior in the mother’s brain (7). At birth, OXT serves to protect 
the fetal brain from the hypoxic conditions of birth by triggering a 
transient switch in -aminobutyric acid signaling (8), along with sev-
eral other related functions (9–12). The process by which exposure 
to a hormone in early life produces an enduring effect in the devel-
oping organism is known as “hormonal imprinting,” which has been 
observed following OXT exposure (13). The neonatal period ap-
pears to be a sensitive period in terms of OXT’s actions within the 
brain (6, 13, 14). This suggests that changes in perinatal OXT sig-
naling can alter developmental trajectory. Following birth and 
across development, OXT regulates a variety of social behaviors 
typically associated with affiliation, caregiving, and bonding (15). 
We therefore hypothesized that OXT exposure at birth could in-
fluence subsequent social behavior.
In humans, labor induction is associated with changes in neonatal 
behavior (16) and delayed motor development (17) in the acute phase 
soon after birth. There has been little work done on the possible long-
term consequences of OXT exposure beyond some inconsistent as-
sociations between maternal OXT administration (either induction 
or augmentation) and heightened risk for later development of au-
tism in offspring (18–21). However, all of these associations have been 
correlational, and we do not know whether this association is due to 
the administration of exogenous OXT per se or the need for such 
administration is due to low endogenous OXT levels.
Here, we used the monogamous prairie vole to experimentally in-
vestigate the effects of maternally administered OXT in the immedi-
ate prepartum period on the brains and behavior of offspring. As a 
proof of concept, we tested whether maternal administration of a sin-
gle IU of OXT (0.03 mg/kg) would produce acute physiological effects 
in the fetus (plasma OXT levels and c-fos immunoreactivity in the 
brain). Second, we sought to confirm fetal physiological sensitivity to 
maternal OXT without the confounding influence of induced uterine 
contractions and hence tested fetal heart rate following removal from 
the uterus while still maintaining the umbilical connection. Next, we 
tested how long-lasting consequences of OXT could be established in 
the fetal brain via changes to the epigenetic regulation of the OXT 
receptor (Oxtr) following a single administration of OXT (0.125 to 
0.5 mg/kg, administered once on the expected day of delivery). Last, 
we used the intermediate dose of OXT (0.25 mg/kg) administered 
maternally on the day of delivery to explore the effects on offspring 
brain and behavior. The range of doses chosen for this study was based 
on previous work from our laboratory that used 0.4 mg/kg of OXT 
administered to voles daily (22) and 1 mg/kg administered once to 
pups on the first postnatal day (15, 23). Prairie voles have relatively 
high levels of plasma OXT (24), so the doses used in the present work 
are high by the standards of other species but still below threshold to 
induce labor in the vole.
RESULTS
The fetus is sensitive to maternally administered OXT
In experiments 1 and 2, we measured acute physiological responses 
of the fetus to maternal OXT administration to establish fetal sensitivity 
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to maternal OXT. Maternally administered OXT (0.03 mg/kg) on the 
expected day of delivery resulted in increased fetal plasma OXT levels 
(experiment 1, P < 0.05; Fig. 1A) as well as an increase in neuronal 
activity in two OXT-sensitive regions, the paraventricular nucleus 
and supraoptic nucleus, both located within the hypothalamus (P < 0.05 
for both comparisons; Fig. 1, B and C). Since OXT produces acute 
bradycardic effect in adults (25), we assessed the acute effect of OXT 
on heart rate in fetal voles in experiment 2. Similar to adults, direct 
administration of OXT (0.25 mg/kg) to vole fetuses produced an acute 
bradycardic response 5 min after injection (experiment 2, P < 0.05; 
Fig. 1D). Next, we tested whether maternally administered OXT 
would have a similar effect. To remove the confounding influence of 
uterine contractions restricting blood supply and thereby slowing 
fetal heart rate, we removed fetal pups from the uterus and excised 
them via laparotomy while still maintaining a connection to the 
maternal circulation via the umbilical cord (experiment 2b; Fig. 1E). In-
traperitoneal administration of OXT to the dam produced a rapid de-
crease in fetal heart rate (Fig. 1F). The fetal heart rate decline continued 
Fig. 1. The fetus is acutely responsive to maternal OXT. (A) Experiment 1a: Plasma OXT was higher in fetal vole pups after maternal treatment with OXT (0.03 mg/kg, 
n = 6) compared to saline vehicle (SAL, n = 7). Results from two OXT litters were discarded because of excessively high values that fell beyond the linear portion of the 
assay’s sensitivity curve. (B and C) Experiment 1b: In a separate set of animals, the number of c-fos + nuclei was higher in fetal vole pups after maternal treatment with 
OXT (0.03 mg/kg, n = 9) compared to SAL (n = 10) in both the paraventricular nucleus (PVN) (B) and supraoptic nucleus (SON) (C). (D) Experiment 2a: Heart rate in postnatal 
day 1 (PND 1) vole pups was lower after direct injection of OXT (0.25 mg/kg, n = 7) compared to SAL (n = 7). (E) Experiment 2b: Heart rate recording paradigm for term 
fetal vole pups while still connected to maternal blood supply via the umbilical cord. (F) Representative traces of fetal heart rate from experiment 2b. (G) Heart rate in fetal vole 
pups (approximately embryonic day 21) was lower after maternal OXT treatment (0.25 mg/kg, n = 6) compared to SAL (n = 7); this was prevented by pretreatment with 
an OXT antagonist (OTA, 2 mg/kg, n = 5) 10 min prior. Data are presented as 5 min of baseline with maternal treatment occurring at the time point denoted by the black 
triangle, followed by another 5 min of recording. Data shown are means ± SEM *P < 0.05; **P < 0.01.
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over the course of the 5-min recording, an effect not seen in the group 
treated with saline vehicle (SAL) (P < 0.01; Fig. 1G). Pretreatment 
with the OXT antagonist L-368,899 (OTA) completely abolished 
this effect (P < 0.01, Fig. 1G). There were no effects of sex on fetal heart 
rate. OTA also led to a higher resting heart rate in the fetus, which sug-
gests a tonically bradycardic role for OXT. Thus, we conclude that 
the fetal vole pup is acutely sensitive to maternally administered OXT.
Maternally administered OXT leads to regulatory changes  
in fetal Oxtr
In experiment 3, we measured Oxtr DNA methylation as a percentage of 
CpGs (cytosines prior to guanines) that were methylated across four sites 
conserved between prairie voles and humans (Fig. 2A) (26) at 90 min after 
maternal OXT administration (0.125 to 0.5 mg/kg). Variation in fetal 
weight served as a proxy for gestational development and revealed 
that expression and epigenetic regulation of Oxtr appear to change as par-
turition approaches. As predicted by the canonical relationship be-
tween methylation and transcription, Oxtr methylation negatively 
predicted Oxtr mRNA levels (Fig. 2C). Across all three brain regions, 
increasing fetal weight was negatively correlated with Oxtr methyla-
tion (Fig. 2D) and positively correlated with Oxtr mRNA expression 
(Fig. 2E). Analyses of Oxtr methylation revealed an effect of fetal 
weight [F(1,1071) = 11.16, P < 0.001] and a dose × fetal weight in-
teraction [F(1,1071) = 6.01, P = 0.014], such that methylation was 
higher in the OXT-treated groups among heavier pups. Oxtr ex-
pression was evaluated as proportional to GAPDH mRNA, repeated 
throughout the same three brain regions, and analyses revealed ef-
fects of fetal weight [F(1,80) = 6.05, P = 0.016] and region [F(2,133) = 
5.11, P = 0.007], as well as a dose × fetal weight × methylation × region 
interaction [F(2,132) = 11.05, P < 0.001], such that fetal weight led to 
increases in Oxtr expression, and methylation was generally associ-
ated with decreases in Oxtr expression.
OXT treatment also affected the relationship between fetal weight 
and Oxtr regulation, especially in the high-OXT treatment group 
(0.5 mg/kg). We observed a dose-dependent increase in the slope of 
the weight-methylation relationship (Fig. 2D). For each of the rela-
tionships examined, i.e., (i) Oxtr methylation−fetal weight, (ii) Oxtr 
expression−fetal weight, and (iii) Oxtr expression−Oxtr methylation, 
there were significant correlations for the saline and no-treatment 
conditions (P < 0.05) but not for any of the OXT doses (Fig. 2, C to E). For 
a given weight, there was a dose-dependent increase in methylation 
across the three brain regions (Fig. 2, F and I to K). The relationship 
between methylation level and transcription remained the same but 
was shifted upward in the high-OXT group (Fig. 2C). For a given 
weight and degree of methylation, the high-OXT group responded 
with increased Oxtr expression (Fig. 2, N and O). There were no ef-
fects of either maternal OXT treatment or fetal body weight on ex-
pression levels of the vasopressin receptor V1aR, and no effect of 
sex on any measure, except V1aR expression, which was higher in 
males throughout the brain (P < 0.05).
Maternally administered OXT leads to changes in offspring 
social behavior throughout development
In experiment 4, we evaluated the impact of maternally administered 
OXT (0.25 mg/kg) at birth on offspring behavior throughout devel-
opment. To account for the possibility of prenatal OXT affecting ma-
ternal behavior and thereby indirectly affecting offspring development, 
we implemented a cross-fostering paradigm (Fig. 3A). Because OXT has 
been shown to affect the production of ultrasonic vocalizations (USVs) 
in rodent pups (27), we chose to first examine this behavior. Overall, 
there were significant effects of age [F(22,167) = 5.397, P < 0.001], 
treatment [F(22,167) = 2.419, P = 0.001], and an interaction between 
treatment and sex [F(44,336) = 1.572, P = 0.015] such that male SAL 
pups vocalized for a longer duration than female SAL pups (P = 0.049). 
Across postnatal days 1 and 4, vole pups born to OXT-treated dams 
emitted more vocalizations (P = 0.013; Fig. 3B) and vocalized for lon-
ger (P = 0.002; Fig. 3C). There were no differences in pup weights at 
any age. In addition, we observed no differences in maternal time 
spent on the nest as a result of OXT administration (fig. S1).
At weaning age (postnatal day 20), offspring were tested for anxiety- 
like behavior in the open-field test (OFT) since OXT has been im-
plicated in the regulation of anxiety (28). We observed no treatment 
effects nor sex differences in anxiety-like behavior (Fig. 3D). As sub-
adults (postnatal days 50 to 55), offspring were tested for caregiving 
behavior in the alloparental care test (APC) since OXT has been im-
plicated in the regulation of alloparenting (29, 30). As has been pre-
viously reported (31), we observed a significant effect of sex, such 
that male voles were more alloparental than females [F(5,55) = 6.208, 
P < 0.001]. In addition, there was a main effect of treatment [F(5,55) = 
4.43, P = 0.002], such that offspring of OXT-treated dams displayed 
more alloparental caregiving (Fig. 3, E and F). The proportion of sub-
jects attacking the pup did not vary between treatment conditions (SAL 
females: 12 of 31, OXT females: 14 of 28, SAL males: 5 of 21, and OXT 
males: 3 of 17). The USV, OFT, and APC findings were all replica-
tions from a preliminary study conducted without cross-fostering 
that showed a similar pattern of effects, albeit within the OXT-treated 
group, only females were more alloparental (fig. S2).
As adults (postnatal day 60), offspring were paired with an opposite 
sex conspecific and tested for partner preference formation in the partner 
preference test (PPT) since OXT has been implicated in social bonding 
and monogamy (32). Here, we observed that whereas females of both 
treatment conditions formed partner preferences, males did not (Fig. 4B). 
When time spent side-by-side huddling was collapsed across Part-
ner and Stranger, offspring of OXT-treated dams spent more time 
side-by-side huddling compared to offspring of saline-treated dams 
[F(1,90) = 4.21, P = 0.015; Fig. 4C] and less time alone in the solitary 
cage [F(1,90) = 12.86, P = 0.001; Fig. 4D]. There was also a trend of 
offspring of OXT-treated dams spending more time in the Stranger’s 
cage (P = 0.056) and huddling with the Stranger (P = 0.056), along 
with a sex × treatment interaction indicating more time spent in the 
Partner’s cage [F(1,90) = 4.98, P = 0.028] among females of the OXT 
condition. In none of the behavioral measures tested did we observe 
an effect of rearing condition, that is, the treatment of the foster dam.
Maternally administered OXT leads to changes in the 
endogenous OXT system within the brains of adult offspring
Following completion of this battery of behavioral tests, subjects were 
euthanized, and brain tissue was collected and immediately frozen. 
To examine the effects of OXT (0.25 mg/kg) exposure in early life on 
the state of endogenous OXT regulation in adulthood, we dissected 
brains for regional analysis of Oxtr at the level of DNA methylation, 
mRNA expression, and protein levels.
Autoradiographic analyses revealed sex- and region-specific changes 
in neuropeptide receptor densities in adulthood. The adult male off-
spring of OXT-treated dams displayed increased OXTR density across 
several brain regions (Fig. 5). We observed sex × treatment interac-
tion effects on OXTR density in the central amygdala [F(1,67) = 4.3, 
P = 0.042; Fig. 5K], parietal cortex [F(1,68) = 5.03, P = 0.028; Fig. 5L], 
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Fig. 2. DNA methylation of Oxtr promoter within the fetal brain is reduced with advancing gestation but increased by maternal OXT. Experiment 3: The methyl-
ation and expression of Oxtr in fetal vole pup brains on the expected day of delivery and the acute effects of maternal OXT administration. (A) Sequence homology be-
tween human and prairie vole Oxtr genes with respect to four CpG sites assayed in this study. (B) Treatment key for the following graphs of data from approximately 
embryonic day 21 fetal vole pup brains (n = 15 to 22 per group). (C) Oxtr expression was significantly negatively predicted by Oxtr methylation in the saline and no-treatment 
conditions and not in the OXT treatment conditions. Oxtr expression was measured relative to GAPDH expression using the Ct method (2−Ct). (D) Oxtr DNA methylation 
was significantly negatively predicted by fetal weight in the saline and no-treatment conditions and not in the OXT treatment conditions. (E) Oxtr expression was signifi-
cantly positively predicted by fetal weight in the saline and no-treatment conditions and not in the OXT treatment conditions. (F to H) The overall differences in Oxtr 
methylation between treatment conditions revealed higher methylation in the high-dose OXT condition compared to the no-treatment condition across all three brain 
regions. (I to K) Once fetal body weight was taken into account, there was a dose-dependent increase in Oxtr DNA methylation for a given fetal weight, with the high-dose 
OXT condition showing higher methylation levels than other conditions across all three brain regions. (L) Looking across the entire fetal brain, there was a dose-dependent 
increase in Oxtr DNA methylation for a given fetal weight following OXT treatment based on the expected relationship between fetal body weight and Oxtr methylation 
observed in the no-treatment condition. (M) Looking across the entire fetal brain, there were no treatment effects on the relationship between fetal weight and Oxtr ex-
pression level. (N) Looking across the entire fetal brain, the high-OXT treatment produced an increase in the level of Oxtr expression relative to the expected level of ex-
pression based on fetal body weight and Oxtr methylation observed in the no-treatment condition. This effect was most prominent in the forebrain (O), somewhat present 
in the midbrain, (P) and absent in the hindbrain (Q). Significant differences between groups are illustrated by different lowercase letters above each bar; groups 
sharing the same letter did not differ.
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Fig. 3. Maternal OXT at birth shapes offspring behavior throughout development. Experiment 4: The behavioral effects of maternal OXT administration across de-
velopment. (A) Experimental design with cross-fostering to examine developmental consequences of maternal OXT administration (0.25 mg/kg) at birth. (B) Offspring 
delivered by OXT-treated dams emitted more vocalizations than offspring delivered by SAL-treated dams on postnatal days 1 and 4 (n = 11 to 20 per group). (C) Offspring 
(1 and 4 days old) delivered by OXT-treated dams vocalized for longer than offspring delivered by SAL-treated dams (n = 11 to 20 per group). (D) No effects of OXT treat-
ment on behavior in the OFT at postnatal day 20. (E) In response to an unfamiliar, unrelated pup, male sex and OXT birth treatment were both associated with increases in allo-
parental caregiving at postnatal day 50 (n = 17 to 31 per group). (F) Alloparental caregiving behavior expressed as a proportion of animals within a group displaying each 
behavior, showing the progression from nonresponsive to alloparental over the 20-min time course and including subjects that responded aggressively (attacked). Data 
shown are means ± SEM. *P < 0.05; **P < 0.01. Significant differences between groups in (F) are illustrated by different lowercase letters above each bar; groups sharing 
the same letter did not differ.
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and insular cortex [F(1,53) = 11.46, P = 0.001; F(1,42) = 6.5, P = 0.014; 
and F(1,65) = 7.56, P = 0.008; Fig. 5M]. The insular cortex in partic-
ular, which was measured throughout the rostral-caudal axis of the 
brain at three points, showed a consistent pattern of increased OXTR 
density in males of the OXT birth treatment group. There was a trend 
of sex difference in the lateral septum [F(1,43) = 4.05, P = 0.051], with 
males showing increased OXTR density. No differences in OXTR were 
found in the bed nucleus of the stria terminalis, nucleus accumbens 
(NAcc) (both shell and core), and ventromedial hypothalamus. There 
were several trends for sex differences in V1aR, with males expressing 
V1aR at higher densities, and a sex × treatment effect in the ventral 
pallidum [F(1,58) = 4.31, P = 0.042], with OXT treatment decreasing 
V1aR density in males (fig. S6).
These findings were broadly consistent with molecular results from 
samples of three contralateral brain regions (central amygdala, insular 
cortex, and NAcc; fig. S7). We also observed a consistent pattern of 
females having greater methylation in the Oxtr promoter region than 
males in each of three regions examined (P = 0.003 to 0.025). Last, 
females that spent more time alongside the Partner than the Stranger 
showed consistently less Oxtr promoter methylation (P = 0.002 to 0.03).
DISCUSSION
Here, we have shown that the fetus is acutely sensitive to maternally 
administered OXT at birth and that such OXT exposure changes 
offspring development across a variety of OXT-sensitive brain regions 
and behaviors. This is the first study to show experimentally that there 
can be long-term changes in offspring brain and behavior following 
a single maternal OXT administration in the immediate prepartum. 
When we administered OXT to the pregnant female, fetal OXT lev-
els increased, and neuronal activity in two OXT source nuclei in-
creased. In addition, fetal heart rate declined after maternal OXT 
treatment, which was most likely not caused by uterine contrac-
tions, as the fetus had been removed from the uterus. Maternal 
OXT treatment led to dose-dependent increases in Oxtr methyla-
tion in the fetal brain and increased the Oxtr gene expression for a 
given level of methylation. Offspring exposed to prepartum OXT 
vocalized more following separation as pups and went on to display 
more alloparental care, more time in close proximity with adult con-
specifics, and less time alone. Adult male offspring of OXT-treated dams 
showed increases in OXTR and a decrease in V1aR density in re-
gions of the brain known to regulate social behavior and affect. 
When we used a cross-fostering paradigm to determine the contri-
bution of possible OXT-induced changes in maternal behavior, we 
saw no effects of rearing condition on any behavior measured. We 
therefore conclude that the observed changes are via direct action of 
maternally administered OXT on the fetus, possibly by crossing the 
placenta, as has been shown previously (33).
Evidence continues to grow that OXT acts as a hormonal signal 
that prepares the fetal brain for the extrauterine environment (6). Thus, 
there is an adaptive reason why the fetal brain would be sensitive to ma-
ternal OXT levels, and the observed changes in offspring development 
Fig. 4. The behavioral effects of maternal OXT administration on pair bonding in adulthood (experiment 4 continued). (A) The PPT paradigm, where a given subject is free to 
spend time with either of two conspecifics of the opposite sex, one unfamiliar (Stranger) and one with which the subject has cohabited for 24 hours (Partner), tested here in 
adulthood on postnatal day 60. (B) Partner preference formation, indexed by significantly more time spent in side-by-side contact with the Partner versus Stranger, was achieved in fe-
males of both treatment conditions (n = 16 to 29 per group). (C) When collapsed across both Partner and Stranger, OXT-treated animals showed increased total time in side-by-side contact 
(n = 16 to 29 per group). (D) OXT treatment was also associated with less time spent in the solitary cage (n = 16 to 29 per group). Data shown are means ± SEM *P < 0.05; ***P < 0.001.
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may be due to changes in the transition toward homeostatic inde-
pendence. This hypothesis is supported by the molecular results 
from fetal brains. Methylation and expression data suggested that the 
fetal brain becomes more sensitive to OXT as parturition approaches 
(indexed here via fetal weight), since Oxtr methylation levels decreased 
and mRNA levels correspondingly increased.
In the brains of adult male offspring of OXT-treated dams, we 
observed increases in OXTR density in the central amygdala, parietal 
Fig. 5. Maternal OXT administration leads to increased OXTR density in the brains of male offspring in adulthood. Experiment 4 (continued): Autoradiographic 
analyses of OXTR density throughout the brain expressed in terms of optical density (OD). Within-sex comparisons between adult offspring of OXT- and SAL-treated dams 
are shown as heat maps in which blue colors represent regions where SAL-treated animals displayed higher OXTR density and red colors represent regions where OXT-treated 
animals displayed higher OXTR density [n = 11 to 20 per group; females: (A), (E), and (I); males: (B), (F), and (J)]. Comparisons of specific regions of interest (outlined) are 
shown on the right. There were no effects observed in the NAcc core (C), shell (D), or BNST (G). (H) Male sex was associated with a trend toward increased OXTR density 
within the lateral septum. There were multiple sex × treatment interactions revealing that males exposed to OXT treatment condition showed increased OXTR density 
compared to SAL males in the central amygdala (K) and parietal cortex (L) and throughout the anterior-posterior extent of the insular cortex (M). Data shown are 
means ± SEM. †P = 0.051; *P < 0.05; **P < 0.01.
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cortex, and insular cortex and a decrease in V1aR density in the 
ventral pallidum. It is likely that these effects contributed to the be-
havioral differences that we observed in these animals, as these are 
brain regions well known to contribute to the expression of caregiv-
ing behavior (34). OXT signaling in the central amygdala (CeA) 
regulates maternal aggressive behavior in defense of pups (35), while 
OXT in the NAcc regulates pair bonding and alloparental caregiv-
ing (36). Of particular note were the robust increases in OXTR density 
along the rostral-caudal extent of the insular cortex, which is associ-
ated with caregiving responsiveness (34). In addition to the effects 
of maternal OXT treatment, pair-bond formation may have also led 
to changes in OXTR/V1aR densities.
Although there were no differences in overall levels of Oxtr DNA 
methylation within the brain in adulthood (fig. S7), the differences 
in OXTR density were somewhat paralleled by similar changes in 
molecular measures from the corresponding contralateral brain re-
gions. For instance, increases in OXTR density were mirrored by 
increases in Oxtr expression in the amygdala and insular cortex. 
There was also a significant increase and a trend toward an increase 
in the ratio of expression to methylation level in the amygdala and 
insular cortex, respectively. This pattern in the brains of adult off-
spring resembles the changes in epigenetic regulation of Oxtr seen 
in the fetal brain samples and speaks to a possible mechanism by 
which perinatal OXT imparts long-lasting effects. At the acute 90-min 
time point in fetal brains, we observed effects of maternal OXT on 
fetal methylation and mRNA levels, especially at the high dose. Ma-
ternally administered exogenous OXT not only led to increases in 
methylation of the Oxtr promoter but also changed the relationship 
between methylation and mRNA expression. Because expression 
relatively increased for a given level of methylation, we hypothesize 
that this may indicate hydroxymethylation, which has previously 
been associated with increasing gene expression (37). Expression 
levels of the closely related V1aR were not affected, suggesting spec-
ificity of the effects of maternal OXT.
This work builds on previous studies that have shown young 
mammals to be sensitive to the organizational effects of OXT when 
it is administered directly to the pup on the first postnatal day (15, 23). 
Previous studies on the developmental consequences of early-life 
OXT exposure have relied on doses between 1 mg/kg (14, 38–40) 
and 5 mg/kg (13) delivered directly to the pup, rather than to preg-
nant females as in the present study. Previous work on the acute 
functions of maternal OXT on fetal preparedness for birth has used 
doses of 0.05 mg/kg in rats (8) and 1 mg/kg in guinea pigs (10). This 
is roughly in line with species differences in plasma OXT between 
rats and voles, where rat levels are approximately one-third of those 
in voles (24), which implies that higher doses would be needed to 
induce labor in voles. That said, the doses in the present study (0.03 
to 0.5 mg/kg) were below the threshold to induce labor in this spe-
cies. Thus, it is unlikely that the effects observed here were due to 
difficulties with the birth process. However, we cannot exclude in-
direct effects of OXT due to uterine contractions. Note also, that this study 
does not directly model the use of OXT in human labor. Humans 
typically receive much lower doses over much longer durations (41). 
Here, OXT was administered via a single bolus, in contrast to the use 
of a Pitocin drip, which typically involves regularly increasing ad-
ministration rates up to a maximum of 40 mU/min (42). Future work 
should more closely model the dosing regimen used in humans.
The present findings’ relevance to human health should spur future 
studies to investigate the possible effects of maternally adminis-
tered OXT on behavior in human neonates. Currently, approxi-
mately 50% of women are given OXT before the third stage of labor 
(3, 4). Translational animal research is needed to experimentally back-
fill in our understanding of the effects of this widespread practice in 
humans. Although rodent brains are far less developed than humans’ 
at birth, all mammals must navigate the transition from fetal life to 
the extrauterine environment via precise coordination between moth-
er and offspring (43). OXT is one facet of this coordinated transition, 
and practices that affect maternal-fetal hormone signaling may there-
fore affect the fetus’ initiation of homeostatic independence.
Previous studies across human populations have found mixed 
results when examining the links between OXT administration at 
birth and subsequent autism diagnosis in offspring (18–21). The 
present findings suggest that OXT exposure can produce a gregarious 
phenotype in offspring, which would support the contention that a 
correlation between peripartum OXT administration and autism 
may arise because of a heightened need for OXT supplementation 
during labor resulting from low endogenous levels. However, the 
effects of neonatal OXT on subsequent social behavior vary by sex, 
species, and dose (13, 14, 40), so direct extrapolation of the present 
findings to humans is contentious. Even so, these data indicate the 
importance of consideration of OXT dose during labor in humans.
OXT administered to either induce or augment labor should be 
evaluated for potential effects on offspring social/neural development. 
The fact that it has not up to this point speaks to a need for more 
cross-talk between obstetrics and neuroscience, and a reevaluation 
of approaches effectively grandfathered into a widespread obstetric 
practice before we became aware of the diverse set of actions of OXT 
in the brain. We anticipate this process to be extremely challenging, 
as OXT has produced great reductions in fetal and maternal mortality. 
Any unintended side effects to social functioning resulting from pre-
partum OXT will need to be measured alongside the well-documented 
health benefits.
MATERIALS AND METHODS
Experimental design
Heterosexual pairs of prairie voles (Microtus ochrogaster) were used 
to generate the subjects for this study. Dams consisted of primipa-
rous adult female voles at 60 to 90 days of age. All procedures were 
conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and were approved by 
the Institutional Animal Care and Use Committee of either the Uni-
versity of Illinois at Chicago or Northeastern University. Prairie voles 
experience both induced estrus and induced ovulation; therefore, we 
created a timed mating paradigm to best predict the day of delivery 
(Fig. 3A). Untreated sires remained with the dam and litter from con-
ception to weaning. OXT was always administered on the expected 
day of delivery, which was confirmed either by fetal body weight > 
1.7 g or delivery within 24 hours in experiment 4, which focused on 
long-term consequences.
In experiment 1a, term pregnant female prairie voles were intra-
peritoneally injected with either OXT (0.03 mg/kg) or SAL and then 
rapidly decapitated 10 min later to measure peak plasma OXT levels. 
Fetal plasma was then pooled across each litter and assayed for OXT 
according to previously published methods (30). In experiment 1b, 
term pregnant females were treated with either OXT (0.03 mg/kg) or 
SAL and then anesthetized with isoflurane 90 min later to measure 
peak c-fos immunoreactivity. Fetal brains were then embedded in 
Kenkel et al., Sci. Adv. 2019; 5 : eaav2244     1 May 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 10
gelatin and processed for c-fos immunohistochemistry according to 
previously published methods (44).
In experiments 2a and 2b, pup/fetal heart rate was obtained by 
looping leads around opposite limbs (Fig. 1C) and applying electrode- 
conductive gel. In experiment 2a, the umbilical cord was clamped to pre-
vent transfer, and the fetus was injected directly. In experiment 2b, 
the fetus was still connected to the maternal circulation via the um-
bilical cord and the pregnant female was injected. After 5 min of base-
line recording, either the pup (experiment 2a, n = 7 per group) or 
pregnant female (experiment 2b, n = 6 to 7 per group) was randomly 
assigned to be injected with either SAL or OXT (0.25 mg/kg) intra-
peritoneally, and heart rate was recorded for another 5 min. In ex-
periment 2b, a third treatment group received pretreatment with the 
OXT antagonist L-368,899 (Merck Pharmaceuticals, Kenilworth, NJ) 
at a dose of 2 mg/kg 10 min before treatment with OXT (n = 5).
In experiment 3, pregnant female prairie voles were randomly 
assigned to receive one of five treatments: low-OXT (0.125 mg/kg), 
medium-OXT (0.25 mg/kg), high-OXT (0.5 mg/kg), SAL, or no treat-
ment on the expected day of delivery (n = 15 to 22 per group). One male 
and one female pup were included from each litter. Ninety minutes 
after treatment, subjects were anesthetized with isoflurane, and fetuses 
were removed and euthanized. Fetal brains were then extracted and 
sectioned into thirds, roughly corresponding to forebrain, midbrain, 
and hindbrain, before being frozen in dry ice and placed into −80°C 
storage. The resulting tissue was then analyzed for Oxtr mRNA ex-
pression and DNA methylation. Oxtr methylation was measured as a 
percentage of CpGs methylated across four sites conserved between 
prairie voles and humans (Fig. 2A) (26).
In experiment 4, pregnant female prairie voles were randomly 
assigned to be injected with either SAL or the medium dose of OXT 
(0.25 mg/kg) on the expected day of delivery. Only if a litter was 
delivered within 24 hours were offspring included in the study and 
cross-fostered to a different dam. After birth, individual pups were 
toe-clipped for identification. Dams each fostered litters comprising 
roughly 50% OXT and 50% SAL pups, balanced by sex as much as 
possible. What resulted was a 2 × 2 × 2 design: birth treatment (the 
treatment of the birth dam), rearing condition (the treatment of the 
foster dam) consisting of either SAL or OXT, and sex. Thus, there were 
eight groups (n = 7 to 18 per group, 101 subjects in total). Offspring 
were then followed throughout development and tested according to 
the paradigm illustrated in Fig. 3A. Specific procedural details can be 
found in the Supplementary Materials.
Statistical analyses
In experiments 1a and 1b, plasma OXT concentrations and regional 
c-fos intensity were compared between treatments by Student’s t test 
(Fig. 1, A to C). In experiments 2a and 2b, heart rate was compared 
between treatments by repeated-measures analysis of variance (ANOVA) 
and presented as either an average (experiment 2a; Fig. 1D) or time 
series (experiment 2b; Fig. 1G). In experiment 3, methylation and 
expression were compared between treatments as linear mixed- 
effects models that included fetal sex, fetal weight, litter size, and 
dose of OXT (and in the case of expression, methylation as well). 
Methylation data are also presented as the residuals of methylation 
as a function of fetal weight for a linear model based solely on the 
no-treatment control group (Fig. 2, F to K). Expression data are also 
presented as the residuals of expression as a function of fetal weight 
and methylation for a linear model based solely on the no-treatment 
control group (Fig. 2, L to N). In experiment 4, behaviors were com-
pared between birth and rearing treatments as follows: for USVs, a 
repeated-measures ANOVA that included age, sex, birth treatment, 
and rearing treatment; for OFT, APC, and PPT behaviors, ANOVAs 
that included sex, birth treatment, and rearing treatment. For the mo-
lecular measures in adult brains, Oxtr methylation and mRNA expres-
sion were evaluated via an ANOVA that included sex, birth treatment, 
and brain region. For the autoradiographic analyses in adult brains, 
OXTR and V1aR were evaluated via a repeated-measures ANOVA (two 
repetitions per brain region) that included sex, birth treatment, and 
brain region. We did not observe any effects of litter size.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/5/eaav2244/DC1
Supplementary Methods
Fig. S1. Postnatal development and care.
Fig. S2. C-fos immunoreactivity. 
Fig. S3. Behavioral results on the effects of maternal OXT administration (0.25 mg/kg, 
intraperitoneally) from an earlier study without cross-fostering.
Fig. S4. The workflow for consolidating autoradiographic images into group composites, 
which were then subtracted from one another to generate heat maps of group differentials.
Fig. S5. Autoradiographic analyses of OXTR density throughout the brain.
Fig. S6. Autoradiographic analyses of V1aR density throughout the brain.
Fig. S7. The effects of maternal OXT administration on offspring Oxtr expression and 
methylation in adulthood, experiment 4 (continued).
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